Strengthening the company’s innovative potential through the development of the R & D department in Ethifarm Sp. z o.o. Sp. z o.o. K.
The project concerns the purchase of innovative laboratory equipment enabling R & D work on a new medicinal product at the Ethifarm Pharmaceutical Plant. As part of the project, the applicant plans to purchase fixed assets:(a) a device for testing the release of x2b) liquid chromatography apparatus (HPLC) together with softwaremc (gas chromatography apparatus together with softwaremd) viscosemeter The aim of the project is to carry out R & D work on the development of a generic drug for the medicinal product Praxilene (100 mg capsules) produced by the laboratories Merck Sante S.A.A. The active substance of the indicated product is naphthidrofuryl hydrogen olate, which is a serotonin receptor inhibitor. The drug is classified as a so-called drug. ‘metabolisers’ and is used for problems with blood circulation and treatment of peripheral vascular disorders. Ethifarm Sp. z o.o. Sp. K. will introduce on the Polish market generic of the above preparation NAFTIL (capsules 100 mg). Currently, naphthidrofuryl hydrogen oxalate is not available in Poland as an active substance. Praxilene together with Cilostazol is a medicine of choice used to treat chronic insufficiency of the lower limbs. It is used in the United States, the United Kingdom and most Western countries. It is worth noting that Praxilene in relation to Cilostazol exhibits a better safety profile and a lower cost of therapy.The project shows signs of product innovation (development of a new drug), process (implementation of new analytical techniques) and non-technological (organisation) on a national scale.Number of companies receiving support: 1 units Number of companies receiving grants: Private investment complementing public support to enterprises (grants): 260 150,000 plnNumber of research laboratories supported: 1 pcs.Investment outlays for the purchase of research equipment: 744 150,00 pln